Korea Investment CORP Cuts Stock Position in The Cooper Companies, Inc. $COO

Key Points

• Korea Investment CORP reduced its stake in The Cooper Companies, Inc. by 4.8%, selling 4,300 shares, and now holds 85,615 shares valued at approximately $7.22 million.
• Analysts have varied outlooks on Cooper Companies, with the average price target currently set at $96.73, showing a mix of ratings including one "Strong Buy" and nine "Buy" ratings.
• The Cooper Companies reported a 6.3% increase in revenue year-over-year, achieving $1 billion in revenue for the latest quarter, exceeding analyst expectations.

Korea Investment CORP decreased its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 4.8% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 85,615 shares of the medical device company's stock after selling 4,300 shares during the quarter. Korea Investment CORP's holdings in Cooper Companies were worth $7,222,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. JPMorgan Chase & Co. increased its holdings in Cooper Companies by 3.4% during the first quarter. JPMorgan Chase & Co. now owns 5,177,008 shares of the medical device company's stock worth $436,681,000 after buying an additional 172,485 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Cooper Companies by 17.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,734,327 shares of the medical device company's stock worth $399,340,000 after purchasing an additional 686,751 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Cooper Companies by 517.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,529,477 shares of the medical device company's stock worth $324,466,000 after purchasing an additional 2,957,421 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Cooper Companies by 15.4% in the 4th quarter. Northern Trust Corp now owns 2,018,898 shares of the medical device company's stock valued at $185,597,000 after purchasing an additional 268,972 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Cooper Companies by 1.0% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,836,892 shares of the medical device company's stock valued at $168,865,000 after purchasing an additional 18,282 shares during the last quarter. Institutional investors and hedge funds own 24.39% of the company's stock.

Cooper Companies Price Performance

Shares of Cooper Companies stock traded up $0.18 during midday trading on Tuesday, hitting $73.66. 4,307,279 shares of the company traded hands, compared to its average volume of 2,166,872. The firm's fifty day moving average price is $72.25 and its 200-day moving average price is $77.94. The stock has a market cap of $14.73 billion, a price-to-earnings ratio of 35.76, a PEG ratio of 1.83 and a beta of 1.00. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.23 and a current ratio of 2.10. The Cooper Companies, Inc. has a 12 month low of $65.00 and a 12 month high of $112.38.

Cooper Companies (NASDAQ:COO - Get Free Report) last announced its earnings results on Thursday, May 29th. The medical device company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.03. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $995.12 million. Cooper Companies had a return on equity of 9.60% and a net margin of 10.39%.Cooper Companies's revenue for the quarter was up 6.3% compared to the same quarter last year. During the same period last year, the company earned $0.85 EPS. Cooper Companies has set its FY 2025 guidance at 4.050-4.110 EPS. As a group, sell-side analysts forecast that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on COO. BNP Paribas raised Cooper Companies from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 22nd. Needham & Company LLC raised shares of Cooper Companies from a "hold" rating to a "buy" rating and set a $94.00 price target on the stock in a research report on Tuesday, June 17th. Mizuho cut their price objective on shares of Cooper Companies from $105.00 to $90.00 and set an "outperform" rating for the company in a report on Wednesday, July 16th. Wall Street Zen lowered shares of Cooper Companies from a "buy" rating to a "hold" rating in a research report on Saturday, July 12th. Finally, UBS Group upgraded shares of Cooper Companies to a "buy" rating in a research report on Tuesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $96.73.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.